These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24007468)

  • 1. Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort.
    Suárez-García I; Sobrino-Vegas P; Tejada A; Viciana P; Ribas M; Iribarren J; Díaz Menéndez M; Rivero M; Arazo P; Del Amo J; Moreno S;
    HIV Med; 2014 Feb; 15(2):86-97. PubMed ID: 24007468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of patients infected with HIV through use of injected drugs compared to patients infected through sexual transmission: late presentation, delayed anti-retroviral treatment and higher mortality.
    Suárez-García I; Sobrino-Vegas P; Dalmau D; Rubio R; Iribarren JA; Blanco JR; Gutierrez F; Montero Alonso M; Bernal E; Vinuesa García D; Del Amo J;
    Addiction; 2016 Jul; 111(7):1235-45. PubMed ID: 26890155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between antiretroviral prescription patterns and treatment guidelines in treatment-naïve HIV-1-infected patients.
    Suarez-Lozano I; Viciana P; Lacalle JR; Teira R; Lozano F; Lopez-Aldeguer J; Pedrol E; Domingo P; Cosin J; Roca B; Geijo P; Fuente B; Vergara A; Ribera E; Galindo MJ; Zapata A; Sanchez T; Vidal F; Munoz-Sanz A; Munoz-Sanchez J; Garrido M
    HIV Med; 2009 Oct; 10(9):573-9. PubMed ID: 19785666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015.
    Suárez-García I; González J; Berenguer J; García F; Portilla J; Muga R; Moreno S; Jarrín I;
    Enferm Infecc Microbiol Clin (Engl Ed); 2019 Nov; 37(9):580-587. PubMed ID: 30982676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care.
    Sobrino-Vegas P; Rodríguez-Urrego J; Berenguer J; Caro-Murillo AM; Blanco JR; Viciana P; Moreno S; Bernardino I; del Amo J;
    Antivir Ther; 2012; 17(1):1-8. PubMed ID: 22267463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].
    ;
    Enferm Infecc Microbiol Clin; 2007 Jan; 25(1):32-53. PubMed ID: 17261244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice.
    Moreno A; Perez-Elías MJ; Casado JL; Muñoz V; Antela A; Dronda F; Navas E; Fortún J; Quereda C; Moreno S
    Antivir Ther; 2000 Dec; 5(4):243-8. PubMed ID: 11142618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.